Phenylalanine

Phenylalanine

SCHEMBL4612447

NCC(=O)O.NCC(=O)O.NCC(=O)O.N[C@@H](Cc1ccccc1)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
CTSC P53634 2/20 0.49
DPP4 P27487 3/20 0.42
DPP8 Q6V1X1 2/20 0.42
DPP9 Q86TI2 2/20 0.42
DPP7 Q9UHL4 2/20 0.42
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
SLC15A1 P46059 1/20 0.42
FAP Q12884 1/20 0.40
LTA4H P09960 1/20 0.40
ACE P12821 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
REN P00797 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylalanine SCHEMBL3103204 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL29198065 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27683462 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27683458 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL10428633 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL2764420 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL4405170 1.00 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL4612406 0.95 SLC7A5 (0.49) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL4614788 0.95 SLC7A5 (0.49) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27702676 0.95 SLC7A5 (0.49) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1054677-B1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES CONNECTIVE TISSUE IMAGINEERING (US) 2008-10-22 EP claimed
EP-1064010-B1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2008-02-20 EP claimed
EP-1064010-A4 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2004-10-06 EP claimed
US-6777389-B1 INHIBITING CUTANEOUS EFFECTS OF AGING CONNECTIVE TISSUE IMAGINEERING LLC 2004-08-17 US claimed
CN-1300220-A Peptide compositions and formulations and use of same MRS LTD (US) 2001-06-20 CN claimed
EP-1064010-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME Mrs, Llc (US) 2001-01-03 EP claimed
WO-1999045941-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME MRS, LLC (US) 1999-09-16 WO claimed
EP-1054677-B1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES CONNECTIVE TISSUE IMAGINEERING (US) 2008-10-22 EP disclosed
EP-1064010-B1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2008-02-20 EP disclosed
EP-1392346-A4 COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE CONNECTIVE TISSUE IMAGINEERING (US) 2006-10-25 EP disclosed
EP-1054677-A4 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES MRS LLC (US) 2005-07-27 EP disclosed
US-20050054578-A1 Elastin peptide analogs and uses thereof SANDBERG LAWRENCE B (US) 2005-03-10 US disclosed
EP-1064010-A4 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME CONNECTIVE TISSUE IMAGINEERING (US) 2004-10-06 EP disclosed
EP-1392346-A2 COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE Connective Tissue Imagineering LLC (US) 2004-03-03 EP disclosed
WO-2001091700-A2 COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE CONNECTIVE TISSUE IMAGINEERING LLC (US) 2001-12-06 WO disclosed
EP-1064010-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME Mrs, Llc (US) 2001-01-03 EP disclosed
EP-1054677-A1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES Mrs, Llc (US) 2000-11-29 EP disclosed
WO-2000028996-A1 COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES MRS, LLC (US) 2000-05-25 WO disclosed
WO-1999045941-A1 PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME MRS, LLC (US) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054578-A1 Elastin peptide analogs and uses thereof ELANE, CUTA, ENPEP SLC7A5 2652/4885ALPI 3157/4885PKM 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.